A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes
Study Details
Study Description
Brief Summary
This is a phase 2 study designed to evaluate the efficacy of daily (QD) oral RGT001-075 GLP1 receptor agonist relative to placebo after up to 16 weeks of double-blind treatment as determined by mean change from baseline in HbA1c in adult patients with Type 2 Diabetes Mellitus (T2DM) who have inadequate glycemic control with diet and exercise and stable metformin treatment.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Dose Group A
|
Drug: RGT001-075
Oral GLP1 Receptor Agonist
|
| Experimental: Dose Group B
|
Drug: RGT001-075
Oral GLP1 Receptor Agonist
|
| Experimental: Dose Group C
|
Drug: RGT001-075
Oral GLP1 Receptor Agonist
|
| Experimental: Dose Group D
|
Drug: RGT001-075
Oral GLP1 Receptor Agonist
|
| Experimental: Dose Group E
|
Drug: RGT001-075
Oral GLP1 Receptor Agonist
|
| Experimental: Dose Group F
|
Drug: RGT001-075
Oral GLP1 Receptor Agonist
|
| Placebo Comparator: Placebo Group
|
Other: Placebo
Placebo comparator
|
Outcome Measures
Primary Outcome Measures
- Change in HbA1c from baseline to end of treatment in the modified intent-to-treat population [up to 16 weeks]
Secondary Outcome Measures
- Change in fasting plasma glucose from baseline to end of treatment in the modified intent-to-treat population [up to 16 weeks]
- Change in mean body weight (absolute and %) from baseline to end of treatment in the modified intent-to-treat population [up to 16 weeks]
- Change in body mass index from baseline to end of treatment in the modified intent-to-treat population [up to 16 weeks]
- Change in waist circumference from baseline to end of treatment in the modified intent-to-treat population [up to 16 weeks]
- Change in mean blood lipids including triglycerides (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) from baseline to end of treatment in the modified intent-to-treat population [up to 16 weeks]
- Percentages of patients achieving HbA1c <6.0%, <6.5%, and/or <7.0% [up to 16 weeks]
- Percentages of patients achieving ≥5% and/or ≥10% greater body weight loss [up to 16 weeks]
- Incidence of treatment-emergent adverse events (TEAE)s, serious adverse events (SAE)s, deaths, and adverse events (AE)s leading to study discontinuation [up to 16 weeks]
- Vital signs - Systolic blood pressure (mmHg) absolute change from baseline [up to 16 weeks]
- Vital signs - Diastolic blood pressure (mmHg) absolute change from baseline [up to 16 weeks]
- Vital signs - Heart rate (beats/minute) absolute change from baseline [up to 16 weeks]
- Vital signs - Body weight (kg) absolute and percent change from baseline [up to 16 weeks]
- Safety clinical laboratories - complete blood count absolute change from baseline [up to 16 weeks]
- Safety clinical laboratories - serum sodium absolute change from baseline [up to 16 weeks]
- Safety clinical laboratories - serum potassium absolute change from baseline [up to 16 weeks]
- Safety clinical laboratories - serum total bilirubin absolute change from baseline [up to 16 weeks]
- Safety clinical laboratories - serum direct bilirubin absolute change from baseline [up to 16 weeks]
- Safety clinical laboratories - serum alkaline phosphatase absolute change from baseline [up to 16 weeks]
- Safety clinical laboratories - serum alanine aminotransferase absolute change from baseline [up to 16 weeks]
- Safety clinical laboratories - serum aspartate aminotransferase absolute change from baseline [up to 16 weeks]
- Safety clinical laboratories - serum blood urea nitrogen absolute change from baseline [up to 16 weeks]
- Safety clinical laboratories - serum creatinine absolute change from baseline [up to 16 weeks]
- Safety clinical laboratories - serum uric acid absolute change from baseline [up to 16 weeks]
- Safety clinical laboratories - serum calcium absolute change from baseline [up to 16 weeks]
- Safety clinical laboratories - serum lipase absolute change from baseline [up to 16 weeks]
- Safety clinical laboratories - serum amylase absolute change from baseline [up to 16 weeks]
- Safety clinical laboratories - eGFR (calculated) absolute change from baseline [up to 16 weeks]
- Safety clinical laboratories - fasting serum glucose absolute change from baseline [up to 16 weeks]
- Safety clinical laboratories - serum albumin absolute change from baseline [up to 16 weeks]
- Safety clinical laboratories - serum total protein absolute change from baseline [up to 16 weeks]
- Safety clinical laboratories - fasting serum total cholesterol absolute change from baseline [up to 16 weeks]
- Safety clinical laboratories - fasting serum triglycerides absolute and percent change from baseline [up to 16 weeks]
- Safety clinical laboratories - fasting serum HDL-C absolute and percent change from baseline [up to 16 weeks]
- Safety clinical laboratories - fasting serum LDL-C absolute and percent change from baseline [up to 16 weeks]
- Safety clinical laboratories - serum calcitonin absolute change from screening [up to 16 weeks]
- ECG interval change from baseline absolute and categorical outliers >450ms [up to 16 weeks]
- Proportion of patients who report AEs of Special Interest (AESI) including GI intolerability, hypoglycemia, drug hypersensitivity reactions, acute pancreatitis, thyroid C-cell hyperplasia and C-cell neoplasms, and cardiovascular (CV) events [up to 16 weeks]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diagnosed with type 2 diabetes that has been treated with lifestyle modification and a stable dose of metformin ≥1000 mg/day (or maximum tolerated dose) for at least 3 months at the time of Screening
-
Screening HbA1c 7.0-10.5%
-
Male or female, age 18-75 years
-
Screening BMI 24.5 - 40 kg/m2
-
Either surgically sterile, abstinent, or willing to use a highly effective method of contraception for the entirety of the study, and not be pregnant or lactating if a woman of child-bearing potential
Exclusion Criteria:
-
Has received within the preceding 3 months prior to Screening, another approved or investigational oral or injectable antidiabetic medication (including, but not limited to sulfonylureas, dipeptidyl peptidase-4 inhibitor [DPP-4i], sodium-glucose cotransport 2 inhibitors, alphaglucosidase inhibitors, meglitinides, thiazolidinediones) or insulin in addition to metformin therapy
-
Has active GI disease including acute or chronic pancreatitis, severe gastroparesis or chronic malabsorption, inflammatory bowel disease, symptomatic gallbladder or biliary disease, known unstable liver disease, a diagnosis of fibrotic nonalcoholic steatohepatitis (NASH), Gilbert's syndrome, or obvious clinical signs or symptoms of liver disease including chronic active hepatitis B or C, or primary biliary cirrhosis, or elevated alanine aminotransferase (ALT) levels at Screening
-
Has any history of myocardial infarction (MI), unstable angina, coronary artery bypass graft, percutaneous coronary therapeutic intervention, transient ischemic attack, stroke, or decompensated congestive heart failure within previous 6 months prior to Screening
-
Has an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2
-
Has active proliferative diabetic retinopathy or macular edema
-
Has a known self or family history (first-degree relative) of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or medullary thyroid cancer
-
Has an active or untreated malignancy or has been in remission from a clinically significant malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for <5 years prior to screening
-
Has evidence of human immunodeficiency virus (HIV) and/or positive HIV antibodies historically or at screening
-
Has had a significant change in weight, defined as a gain or loss of at least 5% body weight in the 3 months prior to screening
-
Has been treated or plan to be treated with drugs or devices or surgery that promote weight loss within 3 months prior to screening
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Axon Clinical Research | Doral | Florida | United States | 33166 |
Sponsors and Collaborators
- Regor Pharmaceuticals Inc.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RGT001-075_01-201